GO:0038156 interleukin-3-mediated signaling pathway: Survival Signaling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038156 describes the molecular cascade triggered when interleukin-3 (IL-3) binds its receptor on the cell surface, culminating in regulation of downstream cellular processes such as transcription.
• IL-3-mediated signaling is a master regulator of hematopoietic cell survival, proliferation, and differentiation, acting primarily through JAK/STAT, PI3K/AKT, and Ras/ERK pathways.
• Key effector proteins include β-catenin, GLUT1, NFIL3/E4BP4, Bcl-xL, and BAD, which collectively control apoptosis, metabolism, and gene expression.
• Dysregulated IL-3 signaling is implicated in myeloid transformation and acute myeloid leukemia (AML), making it a target for leukemia research.
• Negative regulators such as CD45 (a JAK phosphatase) and Spred-1 fine-tune the pathway, preventing excessive or oncogenic signaling.
• CRISPR-based knockout, knock-in, and overexpression models are essential for dissecting the causal roles of individual components in IL-3 signaling.
Description
Interleukin-3 (IL-3) is a pleiotropic cytokine that governs the survival, proliferation, and differentiation of hematopoietic progenitor cells. The signaling cascade initiated by IL-3 binding to its cell-surface receptor is annotated as GO:0038156, the interleukin-3-mediated signaling pathway. This pathway is fundamental to immune cell development and has been extensively studied for its role in leukemia and other hematological disorders. Understanding the molecular events downstream of IL-3 receptor activation is critical for researchers investigating normal hematopoiesis and malignant transformation. The pathway involves rapid phosphorylation events, lipid second messengers, and transcriptional reprogramming that together determine cell fate. Because IL-3 signaling intersects with multiple oncogenic networks, it serves as a paradigm for cytokine receptor signal transduction and a target for therapeutic intervention in myeloid malignancies.
interleukin-3-mediated signaling pathway At A Glance
| GO ID | GO:0038156 |
|---|---|
| GO term | interleukin-3-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | IL-3-mediated signaling pathway; interleukin-3-mediated signalling pathway |
| Major function | Transduces IL-3 receptor signals to regulate survival, proliferation, and gene expression in hematopoietic cells |
| Key downstream pathways | JAK/STAT, PI3K/AKT, Ras/ERK |
| Negative regulators | CD45, Spred-1 |
| Disease relevance | Acute myeloid leukemia, myeloid transformation |
What Is GO:0038156?
GO:0038156, the interleukin-3-mediated signaling pathway, is defined as the series of molecular signals initiated by interleukin-3 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. This biological process encompasses receptor activation, intracellular signal transduction, and the ultimate modulation of gene expression or other cellular responses that dictate cell survival, proliferation, or differentiation.
Why Is interleukin-3-mediated signaling pathway Important in Cell Biology?
The interleukin-3-mediated signaling pathway is essential for the development and function of the immune system, particularly for the survival and expansion of myeloid progenitors and pro-B lymphocytes. Its dysregulation is a driving force in hematological malignancies, notably acute myeloid leukemia, where aberrant IL-3 signaling promotes leukemic cell survival and proliferation. Moreover, the pathway serves as a model for understanding cytokine receptor signaling, with key discoveries about PI3K/AKT-mediated glucose transport and apoptosis regulation having broad implications for cancer biology and metabolism.
• Controls survival of hematopoietic progenitor cells by regulating anti-apoptotic proteins such as Bcl-xL and BAD.
• Drives proliferation of myeloid and lymphoid cells through Ras/ERK and PI3K/AKT cascades.
• Regulates glucose metabolism via GLUT1 translocation, linking cytokine signaling to cellular bioenergetics.
• Modulates β-catenin stability, connecting IL-3 signaling to Wnt-like transcriptional programs in myeloid transformation.
• Involves the transcription factor NFIL3/E4BP4 as a pivotal mediator of IL-3-dependent survival in pro-B lymphocytes.
• Is negatively regulated by CD45, a JAK phosphatase, highlighting the importance of tight control.
• Spred-1 acts as a negative regulator of IL-3-mediated ERK/MAP kinase activation, fine-tuning the response.
• Dysregulation is associated with acute myeloid leukemia and other myeloid neoplasms.
• Provides a paradigm for cytokine receptor signal transduction and therapeutic targeting.
• Offers numerous targets for CRISPR-based functional genomics in hematopoietic cells.
What Happens During interleukin-3-mediated signaling pathway?
IL-3 Binding and Receptor Activation
In simple terms: IL-3 docks onto its receptor on the cell surface, switching it on.
The pathway begins when interleukin-3 binds to its specific cell-surface receptor, a heterodimer composed of an IL-3-specific α chain and a common β chain. This binding induces receptor dimerization and activation of associated JAK kinases, which phosphorylate the receptor and create docking sites for downstream signaling molecules.
PI3K/AKT Pathway Activation and Metabolic Control
In simple terms: A major survival signal is turned on, which also brings more glucose into the cell.
Activated JAKs phosphorylate insulin receptor substrates, leading to recruitment and activation of phosphatidylinositol 3-kinase (PI3K). PI3K generates PIP3, which recruits AKT to the membrane. AKT activation promotes cell survival by phosphorylating BAD and other substrates, and also triggers translocation of the glucose transporter GLUT1 to the cell surface, enhancing glucose uptake.
Ras/ERK MAP Kinase Cascade
In simple terms: Another signal branch tells the cell to grow and divide.
IL-3 also activates the Ras/ERK mitogen-activated protein kinase pathway. This cascade involves Ras activation, Raf, MEK, and ERK phosphorylation, ultimately leading to activation of transcription factors that drive proliferation. Spred-1 negatively regulates this branch by inhibiting Raf activation.
Transcriptional Regulation and Survival Genes
In simple terms: The signals reach the nucleus and switch on genes that keep the cell alive.
Downstream of these kinase cascades, transcription factors such as NFIL3/E4BP4 and STATs are activated. NFIL3/E4BP4 is pivotal for IL-3-mediated survival of pro-B lymphocytes, and its expression is regulated by the Ras-NFIL3 pathway. Additionally, IL-3 signaling stabilizes β-catenin, which can further modulate gene expression linked to myeloid transformation.
Negative Feedback and Termination
In simple terms: Brakes are applied to prevent the signal from going out of control.
The pathway is tightly regulated by phosphatases and inhibitory proteins. CD45 acts as a JAK phosphatase, dephosphorylating JAKs and thereby dampening cytokine receptor signaling. Spred-1 provides another layer of negative regulation by attenuating ERK activation. These feedback mechanisms ensure appropriate signal duration and prevent oncogenic overactivation.
Key Genes Involved in GO:0038156 interleukin-3-mediated signaling pathway
The following genes and proteins are central to the interleukin-3-mediated signaling pathway, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL3 | Ligand that initiates the pathway | Stimulus for receptor activation; used to trigger signaling in experiments |
| IL3RA | IL-3-specific receptor alpha chain | Determines ligand specificity; target for knockout to abolish signaling |
| CSF2RB | Common beta chain shared with GM-CSF and IL-5 receptors | Essential for signal transduction; mutations affect multiple cytokine pathways |
| JAK2 | Janus kinase that phosphorylates receptor and downstream targets | Key kinase; inhibition blocks IL-3 signaling; mutations in myeloproliferative neoplasms |
| STAT5 | Transcription factor activated by JAK2 | Drives expression of survival and proliferation genes |
| PIK3CA | Catalytic subunit of PI3K | Generates PIP3 to recruit AKT; central to survival signaling |
| AKT1 | Serine/threonine kinase | Promotes survival via BAD phosphorylation and GLUT1 translocation |
| BAD | Pro-apoptotic Bcl-2 family member | Phosphorylated and inactivated by AKT; links signaling to apoptosis |
| SLC2A1 (GLUT1) | Glucose transporter | Translocated to cell surface upon IL-3 signaling to increase glucose uptake |
| BCL2L1 (Bcl-xL) | Anti-apoptotic protein | Upregulated by IL-3 signaling to promote survival |
| NFIL3 (E4BP4) | Transcription factor | Pivotal for IL-3-mediated survival of pro-B lymphocytes |
| CTNNB1 (β-catenin) | Transcriptional co-activator | Stabilized by IL-3 signaling; implicated in myeloid transformation |
| MAPK1/3 (ERK1/2) | Mitogen-activated protein kinases | Transduce proliferative signals from Ras |
| SPRED1 | Negative regulator of Ras/ERK pathway | Inhibits IL-3-mediated ERK activation |
| PTPRC (CD45) | JAK phosphatase | Negatively regulates cytokine receptor signaling |
| RAS | Small GTPase | Activates Raf/MEK/ERK cascade |
| RAF1 | Serine/threonine kinase | Phosphorylates MEK in the ERK cascade |
| MEK1/2 | Dual-specificity kinases | Phosphorylate ERK1/2 |
How Is interleukin-3-mediated signaling pathway Regulated?
The interleukin-3-mediated signaling pathway is subject to multiple layers of regulation. Positive regulation occurs through ligand binding and receptor dimerization, while negative regulation is mediated by phosphatases such as CD45, which dephosphorylates JAKs, and by Spred-1, which inhibits the Ras/ERK branch. Additionally, PI3K signaling is counteracted by lipid phosphatases like PTEN (not directly cited in the provided references but implied by general knowledge). The balance between these positive and negative inputs determines the strength and duration of the signal, influencing cell fate decisions.
interleukin-3-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CTNNB1 | Acute myeloid leukemia; myeloid transformation | Knockout or point mutation in AML cell lines to assess β-catenin stabilization |
| BCL2L1 | Leukemia survival; apoptosis resistance | Overexpression or knockout in hematopoietic cells to test IL-3 dependence |
| NFIL3 | Pro-B lymphocyte survival; leukemia | Knockout mice or cell lines to study IL-3-mediated survival |
| SLC2A1 | Metabolic reprogramming in cancer | Knockout or tagged knock-in to track GLUT1 translocation |
| SPRED1 | Myeloid malignancies; ERK hyperactivation | Knockout to enhance ERK signaling; overexpression to suppress |
Acute Myeloid Leukemia
Dysregulated interleukin-3-mediated signaling contributes to myeloid transformation and acute myeloid leukemia (AML). IL-3 signaling stabilizes β-catenin, which promotes leukemic cell proliferation and survival. Targeting this pathway or its downstream effectors may offer therapeutic strategies for AML.
Myeloid Transformation
Aberrant activation of IL-3 signaling pathways, including PI3K/AKT and Ras/ERK, is associated with myeloid transformation. The pathway's ability to enhance glucose uptake and survival gives transformed cells a growth advantage.
Hematopoietic Disorders
Defects in IL-3 signaling can lead to impaired immune cell development, affecting pro-B lymphocyte survival and myeloid progenitor expansion. Understanding these mechanisms is relevant for bone marrow failure and immunodeficiency research.
From interleukin-3-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X mediate IL-3-dependent survival? | CRISPR knockout in IL-3-dependent cell lines (e.g., Ba/F3) |
| Does a specific point mutation in JAK2 alter IL-3 signaling? | Point mutation knock-in using CRISPR in hematopoietic cells |
| How does β-catenin stabilization affect leukemic transformation? | Knock-in of stabilized β-catenin mutant in AML models |
| Where does GLUT1 localize upon IL-3 stimulation? | Tagged knock-in of GLUT1 with fluorescent protein |
| Does overexpression of Spred-1 block ERK activation? | Overexpression of Spred-1 in IL-3-responsive cells |
| What is the transcriptional response to IL-3? | RNA-seq after IL-3 stimulation in wild-type and knockout cells |
How to Study the interleukin-3-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identify IL-3-induced genes and pathways |
| Phosphoproteomics | Phosphorylation sites and kinetics | Map signaling networks downstream of IL-3 receptor |
| Glucose uptake assay | Rate of glucose transport | Assess GLUT1 function and translocation |
| Flow cytometry | Apoptosis, cell surface markers | Measure survival and GLUT1 surface expression |
| Immunoblotting | Protein expression and phosphorylation | Validate activation of AKT, ERK, STAT5 |
| CRISPR screening | Gene essentiality and pathway components | Discover novel regulators of IL-3 signaling |
| Proximity ligation assay | Protein-protein interactions | Visualize receptor complex assembly |
Transcriptomic Analysis (RNA-seq)
RNA sequencing can profile global gene expression changes following IL-3 stimulation, identifying transcriptional targets such as NFIL3/E4BP4 and Bcl-xL. This method is useful for defining the downstream transcriptional program of the pathway.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics enables comprehensive mapping of phosphorylation events downstream of IL-3 receptor activation, including JAK/STAT, PI3K/AKT, and ERK substrates. This approach reveals signaling dynamics and crosstalk.
Metabolic Assays
Glucose uptake assays and cell surface biotinylation can measure GLUT1 translocation in response to IL-3. These methods link cytokine signaling to metabolic reprogramming.
Apoptosis and Survival Assays
Flow cytometry with Annexin V/PI staining and caspase activity assays quantify IL-3-dependent survival. Phospho-BAD and Bcl-xL levels can be assessed by immunoblotting to dissect anti-apoptotic mechanisms.
How CRISPR Can Be Used to Study GO:0038156 interleukin-3-mediated signaling pathway
Knockout
CRISPR knockout of genes such as IL3RA, CSF2RB, JAK2, or NFIL3 can abolish or impair IL-3-mediated signaling, allowing researchers to test their requirement for survival and proliferation. For example, knockout of NFIL3 in pro-B lymphocytes demonstrated its pivotal role in IL-3-mediated survival.
Point Mutation
Introducing specific point mutations (e.g., in JAK2 or β-catenin) via CRISPR can mimic disease-associated variants or phospho-mutants, enabling precise dissection of signaling nodes. This approach is valuable for studying oncogenic mutations in myeloid malignancies.
Knock-in
Knock-in of tagged proteins (e.g., GLUT1-GFP) or reporter genes (e.g., Bcl-xL-luciferase) allows real-time tracking of protein localization and transcriptional activity in response to IL-3. Such models are instrumental for imaging and functional studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can elevate levels of negative regulators like Spred-1 or CD45 to study their inhibitory effects on IL-3 signaling. Overexpression of Bcl-xL can rescue survival in knockout backgrounds, confirming pathway hierarchy.
How EDITGENE Supports interleukin-3-mediated signaling pathway Research
Researchers studying interleukin-3-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in survival, proliferation, or transformation. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of pathway components.
Contact EDITGENE today to design your custom CRISPR model for interleukin-3-mediated signaling pathway research.
Frequently Asked Questions About interleukin-3-mediated signaling pathway
What is the interleukin-3-mediated signaling pathway?
It is the series of molecular signals initiated by interleukin-3 binding to its receptor, leading to regulation of downstream cellular processes such as transcription, as defined by GO:0038156.
What genes are involved in interleukin-3-mediated signaling pathway?
Key genes include IL3, IL3RA, CSF2RB, JAK2, STAT5, PIK3CA, AKT1, BAD, SLC2A1 (GLUT1), BCL2L1, NFIL3, CTNNB1, MAPK1/3, SPRED1, and PTPRC (CD45).
How does interleukin-3 signaling promote cell survival?
IL-3 signaling activates PI3K/AKT, which phosphorylates and inactivates the pro-apoptotic protein BAD, and upregulates anti-apoptotic Bcl-xL. It also induces NFIL3/E4BP4, a transcription factor critical for survival.
What is the role of GLUT1 in interleukin-3 signaling?
IL-3 signaling triggers the translocation of the glucose transporter GLUT1 to the cell surface via a PI3K-dependent mechanism, increasing glucose uptake to support cell survival and proliferation.
How is interleukin-3 signaling negatively regulated?
CD45 acts as a JAK phosphatase to dephosphorylate JAKs, while Spred-1 inhibits the Ras/ERK pathway, together preventing excessive signaling.
What diseases are associated with dysregulated interleukin-3 signaling?
Dysregulation is linked to acute myeloid leukemia and myeloid transformation, where aberrant β-catenin stabilization and enhanced survival contribute to leukemogenesis.
What is the role of NFIL3/E4BP4 in IL-3 signaling?
NFIL3/E4BP4 is a transcription factor pivotal for IL-3-mediated survival of pro-B lymphocytes, acting downstream of the Ras pathway.
How can CRISPR be used to study interleukin-3 signaling?
CRISPR knockout, knock-in, point mutation, and overexpression models allow functional dissection of genes in the pathway, such as JAK2, NFIL3, and GLUT1, in relevant cell lines.
What experimental models are used to study IL-3 signaling?
Common models include IL-3-dependent cell lines (e.g., Ba/F3), primary hematopoietic cells, and CRISPR-engineered derivatives for knockout or knock-in studies.
What is the GO ID for interleukin-3-mediated signaling pathway?
The Gene Ontology ID is GO:0038156, classified under biological_process.
Conclusion
The interleukin-3-mediated signaling pathway (GO:0038156) is a central regulator of hematopoietic cell survival, proliferation, and metabolism. Its intricate network of kinases, phosphatases, and transcription factors ensures appropriate responses to cytokine stimulation, while its dysregulation drives myeloid malignancies such as acute myeloid leukemia. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate its mechanisms and reveal new therapeutic opportunities.
References
- 1. Sadras T et al.. 2014. Interleukin-3-mediated regulation of β-catenin in myeloid transformation and acute myeloid leukemia.. J Leukoc Biol 96(1):83-91 PMID: 24598054
- 2. Craddock BL et al.. 1999. Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling.. J Biol Chem 274(15):10633-40 PMID: 10187860
- 3. Bentley J et al.. 2003. Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface.. J Biol Chem 278(41):39337-48 PMID: 12869574
- 4. Kuribara R et al.. 1999. Two distinct interleukin-3-mediated signal pathways, Ras-NFIL3 (E4BP4) and Bcl-xL, regulate the survival of murine pro-B lymphocytes.. Mol Cell Biol 19(4):2754-62 PMID: 10082541
- 5. Nonami A et al.. 2004. Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells.. J Biol Chem 279(50):52543-51 PMID: 15465815
- 6. Ikushima S et al.. 1997. Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes.. Proc Natl Acad Sci U S A 94(6):2609-14 PMID: 9122243
- 7. Irie-Sasaki J et al.. 2001. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling.. Nature 409(6818):349-54 PMID: 11201744
